HC Wainwright Reiterates "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company's stock. HC Wainwright's target price indicates a potential upside of 148.06% from the company's current price. HC Wainwright also issued estimates for Astria Therapeutics' Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.02) EPS and FY2026 earnings at ($1.87) EPS.

ATXS has been the subject of a number of other research reports. JMP Securities started coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an "outperform" rating and a $26.00 price target for the company. Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. Finally, Oppenheimer increased their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Astria Therapeutics presently has an average rating of "Buy" and a consensus target price of $26.67.

Remove Ads

Astria Therapeutics Stock Performance

Shares of ATXS stock traded down $0.19 during mid-day trading on Tuesday, reaching $6.45. 211,036 shares of the company were exchanged, compared to its average volume of 269,680. Astria Therapeutics has a fifty-two week low of $5.73 and a fifty-two week high of $16.90. The company has a market capitalization of $364.00 million, a P/E ratio of -3.09 and a beta of 0.69. The business's 50 day simple moving average is $7.19 and its 200 day simple moving average is $9.57.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01. On average, analysts forecast that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new position in Astria Therapeutics in the 4th quarter worth about $41,000. Tower Research Capital LLC TRC boosted its holdings in shares of Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Astria Therapeutics in the fourth quarter valued at approximately $50,000. Virtus ETF Advisers LLC bought a new position in shares of Astria Therapeutics in the fourth quarter valued at approximately $65,000. Finally, Quest Partners LLC lifted its stake in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,798 shares during the last quarter. Institutional investors own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.